SEC Form 4 · accession 0001572426-15-000106
Nexvet Biopharma plc · NVET
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Heffernan
Officer — Chief Executive Officer · Director
Period of report
Aug 20, 2015
Accepted (ET)
Aug 20, 2015 · 7:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618561
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Aug 20, 2015 | A | 4,834 | $0.125 | A | 12,084 | D | |
| Ordinary SharesF1 | holding | — | — | — | 234,383 | I | By Mark Andrew and Patricia Louise Heffernan <M&T Heffernan A/C> |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase SharesF2 | $0.125 | Aug 20, 2015 | M | 4,834 | D | Jul 1, 2015 | Jul 1, 2019 | Ordinary Shares | 4,834 | 16,916 | D |
Explanation of responses
- F1The reporting person and his spouse share voting and dispositive power with respect to the reported securities.
- F2The option to purchase 4,834 shares vested on 7/1/15 and was exercised on 8/20/15; the option to purchase 4,833 shares will vest and become exercisable on each of 7/1/16 and 7/1/17. The option to purchase the remaining 7,250 shares will vest and be exercisable upon successful completion of an efficacy trial for any Issuer product, as determined by the Issuer's board of directors; such completion must occur on or before 7/1/19.